9th Annual Biomarkers Congress

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2012 Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis Inflammatory Bowel Disease, In press
2. 2012 The specific linker phosphorylation of Smad2/3 indicates epithelial stem cells in stomach; particularly increasing in mucosae of Helicobacter-associated gastritis Journal of Gastroenterology, In press
3. 2010 Expression of Pituitary Tumor Transforming Gene 1 (PTTG1)/Securin in hepatitis B virus-associated liver diseases: Evidence for a Hepatitis B virus X protein-mediated inhibition of PTTG1 ubiquitination and degradation. Hepatology 51: 777-787.
4. 2009 SKI knockdown inhibits human melanoma tumor growth in vivo. Pigment Cell Melanoma Research 22: 761-772.
5. 2009 Smad2 and Smad3 phosphorylated at both linker and C-terminal regions transmit malignant TGF-b signal in later stages of human colorectal cancer Cancer Research 69: 5321-5330
6. 2009 Hepatitis B virus X protein shifts human hepatic TGF-b signaling from tumor-suppression to oncogenesis in early chronic hepatitis B Hepatology 49: 1203-17.
7. 2009 SP600125, a JNK inhibitor, suppresses rat chemical-induced hepatocellular carcinoma by shifting Smad3 signaling from oncogenesis to tumor-suppression Hepatology 49: 1944-1953.
8. 2009 Modulation of TGF-b signaling during progression of chronic liver diseases Frontiers in Bioscience 14:2923-34
9. 2009 Modulation of the transforming growth factor-1-induced Smad phosphorylation by the extracellular matrix receptor 1-integrin. International Journal of Oncology 35: 1441-1447
10. 2008 TGF-b and hepatocellular carcinoma Hepatology 47: 1095-1096.
11. 2007 Chronic inflammation associated with HCV infection perturbs hepatic   TGF- signaling, promoting cirrhosis and HCC Hepatology 46: 48-57.
12. 2007 Reversible Smad-dependent signaling between tumor suppression and oncogenesis Cancer Research 67: 5090-5096
13. 2006 TGF- during human colorectal carcinogenesis: the shift from epithelial to mesenchymal signaling Inflammopharmacology 14:198-203.
14. 2006 Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis Histology and Histopathology 21: 645-662.
15. 2006 Transforming Growth Factor- during carcinogenesis: the shift from epithelial to mesenchymal signaling Journal of Gastroenterology 41:295-303.
16. 2005 Notch signaling modulates the nuclear localization of carboxy-terminal- phosphorylated smad2 and controls the competence of ectodermal cells for activin A Mechanisms of Development 122: 671-680.
17. 2005 Acceleration of Smad2 and Smad3 Phosphorylation via c-Jun N-terminal Kinase during Human Colorectal Carcinogenesis Cancer Research 65: 157-165.
18. 2005 TGF- and PDGF Signal via JNK-dependent Smad2/3 Phosphorylation in Rat Hepatic Stellate Cells after Acute Liver Injury American Journal of Pathology 166: 1029-1039
19. 2004 TGF- and HGF Transmit the Signals through JNK-Dependent Smad2/3 Phosphorylation at the Linker Regions Oncogene 23: 7416-7429
20. 2003 Distortion of Autocrine TGF- Signal Accelerates Malignant Potential by Enhancing Cell Growth as well as PAI-1 and VEGF Productions in Human Hepatocellular Carcinoma Cells Oncogene 22: 2309-2321
21. 2003 p38 MAPK Mediates Fibrogenic Signal through Smad3 Phosphorylation in   Rat Myofibroblasts Hepatology 38: 879-889.
22. 2001 Specific cell types and their requirements In Basic Cell Culture (ed. Davis J.M.) Second Edition pp. 227-274. Oxford University Press
23. 2000 Differential Regulation of Autocrine TGF- Signal in Hepatic Stellate Cells between Acute and Chronic Rat Liver Injuries Hepatology 35: 49-61
24. 2000 Regulatory Mechanisms for TGF- as Autocrine Inhibitor in Human Hepatocellular Carcinoma: Implications for Roles of Smads in Its Growth Hepatology 32: 218-227.
25. 2000 Autocrine Stimulatory Mechanism by TGF-b in Human Hepatocellular Carcinoma Cancer Research 60: 1394-1402.
26. 2000 Modulation of TGF- Function in Hepatocytes and Hepatic Stellate Cells in Rat Liver Injury Gut 46: 719-724.
27. 2000 Differential Regulation of Activin A Signal Transduction in Hepatocytes and Hepatic Stellate Cells of Rat Liver Injury Journal of Hepatology 32: 251-260.
28. 1999 Down-regulation of TGF- receptors in Human Colorectal Cancer: Implications for Cancer Development. British Journal of Cancer 80 (1/2): 194-205.
29. 1998 Ligand-dependent and -independent interactions with the TGF- type II and I receptor subunits reside in the aminoterminal portion of the ectodomain of the type III subunit. In vitro Cell. Dev. Biol. Anim. 34: 232-238.
30. 1998 Differential Expression of TGF- Receptors in Hepatocytes and Nonparenchymal Cells of Rat Liver Injury. Journal of Hepatology 28: 572-581.
31. 1996 Reconstitution of pentameric complex of dimeric transforming growth factor beta ligand and a type I, II, III receptor in baculoviral -infected insect cells In vitro Cell. Dev. Biol. 32: 345-360
32. 1995 Specific cell types and their requirements In Basic Culture A Practical Approach (ed. Davis J.M.) pp. 181-222. IRL Oxford University Press.
33. 1995 Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism J. Biol. Chem. 270: 6308-6313.
34. 1994 In situ assay of basic fiblobrast growth factor in cultured cells with a specific monoclonal antibody Cell Strut. Func. 18: 333-343.
35. 1994 Genomic structure and cloned cDNAs predict that four variants in the kinase domain of serine / threonine kinase receptors arise by alternative splicing and poly (A) addition Proc. Natl. Acad. Sci. USA. 91: 7957-7961.
36. 1993 A widely expressed transmembrane serine / threonine kinase that does not bind activin, inhibin, transforming growth factor , or bone morphogenic factor J. Biol. Chem. 268: 12719-12723.
37. 1990 Derivation of monoclonal antibody to basic fiblobrast growth factor and its application Method Enzymol. 198: 148-157.
38. 1990 Production of basic fiblobrast growth factor-like factor by cultured human cholangiocellular carcinoma cells. Cancer Science (former Jpn. J. Cancer Res.) 81: 345-354.
39. 1989 Monoclonal antibodies against heparin binding growth factor II (HBGF-II) / basic fiblobrast growth factor (bFGF) that block its biological activity : Invalidity of the antibodies for tumor angiogenesis Proc. Natl. Acad. Sci. USA 86: 9911-9915.

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.